BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21449971)

  • 1. Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma.
    Ding S; Xing N; Lu J; Zhang H; Nishizawa K; Liu S; Yuan X; Qin Y; Liu Y; Ogawa O; Nishiyama H
    Int J Urol; 2011 Jun; 18(6):432-8. PubMed ID: 21449971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B; Miyake H; Nishikawa M; Fujisawa M
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.
    Sun D; Lu J; Ding K; Bi D; Niu Z; Cao Q; Zhang J; Ding S
    Med Oncol; 2013 Mar; 30(1):476. PubMed ID: 23371254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder.
    Khadim MT; Ahmed SA; Khan FA; Ikram A; Shaikh SY
    J Pak Med Assoc; 2015 Aug; 65(8):851-6. PubMed ID: 26228330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
    Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
    Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
    Kim JH; Park J
    Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.
    Kramer MW; Waalkes S; Serth J; Hennenlotter J; Tezval H; Stenzl A; Kuczyk MA; Merseburger AS
    Urol Int; 2011; 87(2):143-50. PubMed ID: 21757871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.